China Investment Roundup: A Summer Of Cross-Border Transactions
It was a busy summer for Chinese pharmaceutical companies and investors who went global shopping, eying mega acquisition deals since China announced plans to accept overseas clinical trial data and global multicenter studies as part of its policies.
You may also be interested in...
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.